Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents as a New Approach to MainTaining VeIn Graft Patency and Reducing Cardiac Events

Trial Profile

Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents as a New Approach to MainTaining VeIn Graft Patency and Reducing Cardiac Events

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms VELETI-II
  • Most Recent Events

    • 26 Oct 2016 Status changed from active, no longer recruiting to discontinued due to slow patient enrolment.
    • 13 May 2014 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 25 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top